In particular, FAK was found to overexpressed and to be highly activated in tumorigenic DU145 and PC-3 cells as well as in prostate cancer tissues from patients with metastasis [52,53] whereas in LNCaP cells that have a lower tumorigenic ability FAK was observed to be much lower [44,52]. This evidence concerns the gene PTK2 and prostate carcinoma.